Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP8B1 Polymorphisms and SGLT2 Inhibitors in T2DM and Obesity
NCT07120828Phase 4Completed
- Sponsor
- Erbil Polytechnic University
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin and dapagliflozin in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Erbil Polytechnic University. Primary endpoints: Change in Body Weight at 6 months, Change in Serum Total Cholesterol at 6 months and 2 more. Started Jul 2025; status: completed.
02
Drugs
empagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07120828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120828.